Paclitaxel is under clinical development by Serb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel (oncogel) was under development for the treatment of esophageal cancer and recurrent glioma. It is adnministered directly into the tumor. The drug candidate is developed based on ReGel drug delivery platform. It is a sustained-release formulation of paclitaxel.
Serb is a pharmaceutical company that develops, markets and distributes prescription medicines for therapeutic niches. The company provides products portfolio such as antidote of organophosphorus compounds, glucocorticoid, colouring agents, lead and mercury chelating agents, products for treatment of drug poisoning, hypothyroidism, and other derivatives. The company offers products in the fields of critical care, toxicology, ophthalmology, endocrinology and infectious diseases products. SERB provides products in the forms of capsules, tablets and injections. It develops its portfolio of niche specialist’s products through research and development to maintain availability of life-saving medicines and answer unmet medical needs. SERB is headquartered in Paris, France.
For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.